Cargando…

Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry

Objective: To evaluate effectiveness, tolerability and safety of an oromucosal spray containing Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), as add-on treatment in patients with severe chronic pain (SCP). Methods: Exploratory analysis of anonymized 12-week routine/open-label data provided by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueberall, Michael A, Essner, Ute, Mueller-Schwefe, Gerhard HH
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535492/ https://www.ncbi.nlm.nih.gov/pubmed/31190969 http://dx.doi.org/10.2147/JPR.S192174

Ejemplares similares

Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2022)

A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain
por: Überall, Michael A
Publicado: (2020)

The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis‐related spasticity
por: Celius, Elisabeth G., et al.
Publicado: (2018)

The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)
por: Grimaldi, Alessandro Enrico, et al.
Publicado: (2019)

Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2021)

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex(®) (THC:CBD, nabiximols) oromucosal spray
por: Etges, Tilden, et al.
Publicado: (2016)

A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity
por: Marinelli, Lucio, et al.
Publicado: (2017)

Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings
por: Flachenecker, Peter, et al.
Publicado: (2018)

Differential inflammatory profile in the lungs of mice exposed to cannabis smoke with varying THC:CBD ratio
por: Haidar, Zahraa, et al.
Publicado: (2023)

Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)
por: Meyer, Thomas, et al.
Publicado: (2019)

Efficacy, tolerability, and safety of an oral enzyme combination vs diclofenac in osteoarthritis of the knee: results of an individual patient-level pooled reanalysis of data from six randomized controlled trials
por: Ueberall, Michael A, et al.
Publicado: (2016)

Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs
por: Chicoine, Alan, et al.
Publicado: (2020)

Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids
por: Ueberall, Michael A, et al.
Publicado: (2015)

A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers
por: Stott, Colin, et al.
Publicado: (2013)

Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice
por: Ueberall, Michael A, et al.
Publicado: (2016)

Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies
por: Akgün, Katja, et al.
Publicado: (2019)

Nanomaterials-Based Electrochemical Δ(9)-THC and CBD Sensors for Chronic Pain
por: Pazuki, Dadbeh, et al.
Publicado: (2023)

Physicians Experience with and Expectations of the Safety and Tolerability of WHO-Step III Opioids for Chronic (Low) Back Pain: Post Hoc Analysis of Data from a German Cross-Sectional Physician Survey
por: Ueberall, Michael A., et al.
Publicado: (2015)

Rapid Distinction and Semiquantitative Analysis of THC and CBD by Silver-Impregnated Paper Spray Mass Spectrometry
por: Huang, Si, et al.
Publicado: (2021)

Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations
por: Ueberall, Michael A, et al.
Publicado: (2016)

A case report of CBD and THC as analgesic therapy in a cat with chronic osteoarthritic pain
por: Gutierre, E, et al.
Publicado: (2023)

CBD, a precursor of THC in e-cigarettes
por: Czégény, Zsuzsanna, et al.
Publicado: (2021)

Long-Term Consequences of Adolescent Exposure to THC-Rich/CBD-Poor and CBD-Rich/THC-Poor Combinations: A Comparison with Pure THC Treatment in Female Rats
por: Gabaglio, Marina, et al.
Publicado: (2021)

Pilot clinical and pharmacokinetic study of Δ(9)-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain
por: Clarke, Stephen, et al.
Publicado: (2022)

A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆(9)-tetrahydrocannabinol (THC) by vaporisation
por: Solowij, Nadia, et al.
Publicado: (2014)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

The Impact of THC and CBD in Schizophrenia: A Systematic Review
por: Ahmed, Saeed, et al.
Publicado: (2021)

THC and CBD: Villain versus Hero? Insights into Adolescent Exposure
por: Pintori, Nicholas, et al.
Publicado: (2023)

The Cannabinoids Δ(8)THC, CBD, and HU-308 Act via Distinct Receptors to Reduce Corneal Pain and Inflammation
por: Thapa, Dinesh, et al.
Publicado: (2018)

Effectiveness and Tolerability of Dronabinol Use in Patients with Chronic Pain: A Retrospective Analysis of 12-Week Open-Label Real-World Data Provided by the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2022)

A Review on Studies of Marijuana for Alzheimer’s Disease – Focusing on CBD, THC
por: Kim, Seok Hee, et al.
Publicado: (2019)

Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?
por: Lachenmeier, Dirk W., et al.
Publicado: (2023)

Potency and Therapeutic THC and CBD Ratios: U.S. Cannabis Markets Overshoot
por: Pennypacker, Sarah D., et al.
Publicado: (2022)

Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX(®)) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials
por: Turri, Mara, et al.
Publicado: (2018)

POTENTIAL BENEFITS OF THC AND CBD IN THE TREATMENT OF HOSPICE-ELIGIBLE DEMENTED AND AGITATED PATIENTS
por: Mintzer, Jacobo`
Publicado: (2022)

Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
por: D’hooghe, Marie, et al.
Publicado: (2021)

Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey
por: Weber, Janet, et al.
Publicado: (2009)

Vape shop owners’/managers’ attitudes about CBD, THC, and marijuana legal markets
por: Berg, Carla J., et al.
Publicado: (2020)

Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC
por: Oultram, Jackson M. J., et al.
Publicado: (2021)

Oromucosal Administration of Interferon to Humans
por: Beilharz, Manfred W., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ikeffe72t6v28gtblivjl1b1fj